A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

The study has 3 periods: a screening phase, a double-blind, double-dummy treatment phase
from the time of randomization to the 26 weeks visit, and an open-label treatment phase of
approximately 12 month duration, where participants will continue treatment with the same
study drug that they were randomized to.

Inclusion Criteria:

- Men and postmenopausal women aged ≥50 who have sustained a unilateral, fracture of
the trochanteric region

- Lumbar spine BMD and/or femoral neck BMD and/or total hip BMD measurement of the
contra lateral hip at least 2.0 SDs (standard deviation) below the average bone mass
for young women and men

Exclusion Criteria:

- Clinically significant abnormal laboratory values

- History of unresolved skeletal diseases that affect bone metabolism

- Polytrauma participants and participants with fractures at more than one site